Tiberiu Pana

Mr. Tiberiu Pana

University of Aberdeen
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2019 in Circulation Research
Verified
Journal Article
Open access
PDF file
MGMarios K. Georgakis
Marios K. Georgakis
RMRainer Malik
Rainer Malik
HBHarry Björkbacka
Harry Björkbacka
TPTiberiu Pana
Tiberiu Pana
SDSerkalem Demissie
Serkalem Demissie
MDMartin Dichgans
Martin Dichgans
Rationale:: Proinflammatory cytokines have been identified as potential targets for lowering vascular risk. Experimental evidence and Mendelian randomization suggest a role of MCP-1 (monocyte chemoattractant protein-1) in atherosclerosis and stroke. However, data from large-scale observational studies are lacking. Objective:: To determine whether circulating levels of MCP-1 are associated with risk of incident stroke in the general population. Methods and Results:: We used previously unpublished data on 17 180 stroke-free individuals (mean age, 56.7±8.1 years; 48.8% men) from 6 population-based prospective cohort studies and explored associations between baseline circulating MCP-1 levels and risk of any stroke, ischemic stroke, and hemorrhagic stroke during a mean follow-up interval of 16.3 years (280 522 person-years at risk; 1435 incident stroke events). We applied Cox proportional-hazards models and pooled hazard ratios (HRs) using random-effects meta-analyses. After adjustments for age, sex, race, and vascular risk factors, higher MCP-1 levels were associated with increased risk of any stroke (HR per 1-SD increment in ln-transformed MCP-1, 1.07; 95% CI, 1.01–1.14). Focusing on stroke subtypes, we found a significant association between baseline MCP-1 levels and higher risk of ischemic stroke (HR, 1.11 [1.02–1.21]) but not hemorrhagic stroke (HR, 1.02 [0.82–1.29]). The results followed a dose-response pattern with a higher risk of ischemic stroke among individuals in the upper quartiles of MCP-1 levels as compared with the first quartile (HRs, second quartile: 1.19 [1.00–1.42]; third quartile: 1.35 [1.14–1.59]; fourth quartile: 1.38 [1.07–1.77]). There was no indication for heterogeneity across studies, and in a subsample of 4 studies (12 516 individuals), the risk estimates were stable after additional adjustments for circulating levels of IL (interleukin)-6 and high-sensitivity CRP (C-reactive protein). Conclusions:: Higher circulating levels of MCP-1 are associated with increased long-term risk of stroke. Our findings along with genetic and experimental evidence suggest that MCP-1 signaling might represent a therapeutic target to lower stroke risk.Visual Overview: An online visual overview is available for this article.

4 November 2020 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
MGMarios K. Georgakis
Marios K. Georgakis
JLJames A. de Lemos
James A. de Lemos
CAColby Ayers
Colby Ayers
BWBiqi Wang
Biqi Wang
HBHarry Björkbacka
Harry Björkbacka
MDMartin Dichgans
Martin Dichgans
The results of the recent Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial, Cardiovascular Inflammation Reduction Trial (CIRT), and Colchicine Cardiovascular Outcomes Trial (COLCOT)1-3 emphasize the promise of targeting specific inflammatory pathways for lowering cardiovascular risk. While recent studies have focused on the interleukin-1β (IL-1β)–interleukin-6 (IL-6)–C-reactive protein (CRP) axis,4 a range of proinflammatory cytokines have been implicated in atherosclerosis.5 In a recent mendelian randomization study examining multiple cytokines, we found genetically predicted levels of monocyte-chemoattractant-protein–1 (MCP-1) to be associated with higher risk of coronary heart disease (CHD) and ischemic stroke.6 The presence of MCP-1 recruits monocytes to the arterial wall, and experimental studies of atherosclerosis suggest that targeting MCP-1 signaling attenuates atherosclerosis progression and plaque destabilization.7,8 Circulating MCP-1 levels have been associated with increased long-term risk of incident stroke,9 but associations with other cardiovascular end points in the general population remain largely unexplored. We leveraged data from 7 population-based cohorts encompassing 21 401 individuals without overt cardiovascular disease and investigated associations of baseline circulating MCP-1 with incident CHD, nonfatal myocardial infarction, and cardiovascular death over a follow-up period extending beyond 20 years.

14 May 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
RTRosa Johanna Thuemmler
Rosa Johanna Thuemmler
TPTiberiu Pana
Tiberiu Pana
BCBen Carter
Ben Carter
RMRibeya Mahmood
Ribeya Mahmood
JBJoao H. Bettencourt-Silva
Joao H. Bettencourt-Silva
Phyo MyintPhyo Myint
Phyo Myint
Hypoalbuminemia associates with poor acute ischemic stroke (AIS) outcomes. We hypothesised a non-linear relationship and aimed to systematically assess this association using prospective stroke data from the Norfolk and Norwich Stroke and TIA Register. Consecutive AIS patients aged ≥40 years admitted December 2003–December 2016 were included. Outcomes: In-hospital mortality, poor discharge, functional outcome (modified Rankin score 3–6), prolonged length of stay (PLoS) > 4 days, and long-term mortality. Restricted cubic spline regressions investigated the albumin–outcome relationship. We updated a systematic review (PubMed, Scopus, and Embase databases, January 2020–June 2023) and undertook a meta-analysis. A total of 9979 patients were included; mean age (standard deviation) = 78.3 (11.2) years; mean serum albumin 36.69 g/L (5.38). Compared to the cohort median, albumin < 37 g/L associated with up to two-fold higher long-term mortality (HRmax; 95% CI = 2.01; 1.61–2.49) and in-hospital mortality (RRmax; 95% CI = 1.48; 1.21–1.80). Albumin > 44 g/L associated with up to 12% higher long-term mortality (HRmax1.12; 1.06–1.19). Nine studies met our inclusion criteria totalling 23,597 patients. Low albumin associated with increased risk of long-term mortality (two studies; relative risk 1.57 (95% CI 1.11–2.22; I2 = 81.28)), as did low-normal albumin (RR 1.10 (95% CI 1.01–1.20; I2 = 0.00)). Strong evidence indicates increased long-term mortality in AIS patients with low or low-normal albumin on admission.

3 February 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
TPTiberiu Pana
Tiberiu Pana
SBSohinee Bhattacharya
Sohinee Bhattacharya
DGDavid T Gamble
David T Gamble
ZPZahra Pasdar
Zahra Pasdar
WSWeronika A Szlachetka
Weronika A Szlachetka
Phyo MyintPhyo Myint
Phyo Myint
Objective We aimed to identify the country-level determinants of the severity of the first wave of the COVID-19 pandemic. Design Ecological study of publicly available data. Countries reporting >25 COVID-19 related deaths until 8 June 2020 were included. The outcome was log mean mortality rate from COVID-19, an estimate of the country-level daily increase in reported deaths during the ascending phase of the epidemic curve. Potential determinants assessed were most recently published demographic parameters (population and population density, percentage population living in urban areas, population >65 years, average body mass index and smoking prevalence); economic parameters (gross domestic product per capita); environmental parameters (pollution levels and mean temperature (January–May); comorbidities (prevalence of diabetes, hypertension and cancer); health system parameters (WHO Health Index and hospital beds per 10 000 population); international arrivals; the stringency index, as a measure of country-level response to COVID-19; BCG vaccination coverage; UV radiation exposure; and testing capacity. Multivariable linear regression was used to analyse the data. Primary outcome Country-level mean mortality rate: the mean slope of the COVID-19 mortality curve during its ascending phase. Participants Thirty-seven countries were included: Algeria, Argentina, Austria, Belgium, Brazil, Canada, Chile, Colombia, the Dominican Republic, Ecuador, Egypt, Finland, France, Germany, Hungary, India, Indonesia, Ireland, Italy, Japan, Mexico, the Netherlands, Peru, the Philippines, Poland, Portugal, Romania, the Russian Federation, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine, the UK and the USA. Results Of all country-level determinants included in the multivariable model, total number of international arrivals (beta 0.033 (95% CI 0.012 to 0.054)) and BCG vaccination coverage (−0.018 (95% CI −0.034 to –0.002)), were significantly associated with the natural logarithm of the mean death rate. Conclusions International travel was directly associated with the mortality slope and thus potentially the spread of COVID-19. Very early restrictions on international travel should be considered to control COVID-19 outbreaks and prevent related deaths.

31 December 2020 in European Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
TPTiberiu Pana
Tiberiu Pana
MDMohsen Dehghani
Mohsen Dehghani
HBHamid Reza Baradaran
Hamid Reza Baradaran
SNSamuel R. Neal
Samuel R. Neal
AWAdrian D. Wood
Adrian D. Wood
Phyo MyintPhyo Myint
Phyo Myint
The role of dietary calcium in cardiovascular disease prevention is unclear. We aimed to determine the association between calcium intake and incident cardiovascular disease and mortality. Data were extracted from the European Prospective Investigation of Cancer, Norfolk (EPIC-Norfolk). Multivariable Cox regressions analysed associations between calcium intake (dietary and supplemental) and cardiovascular disease (myocardial infarction, stroke, heart failure, aortic stenosis, peripheral vascular disease) and mortality (cardiovascular and all-cause). The results of this study were pooled with those from published prospective cohort studies in a meta-analsyis, stratifying by average calcium intake using a 700 mg/day threshold. A total of 17,968 participants aged 40–79 years were followed up for a median of 20.36 years (20.32–20.38). Compared to the first quintile of calcium intake (< 770 mg/day), intakes between 771 and 926 mg/day (second quintile) and 1074–1254 mg/day (fourth quintile) were associated with reduced all-cause mortality (HR 0.91 (0.83–0.99) and 0.85 (0.77–0.93), respectively) and cardiovascular mortality [HR 0.95 (0.87–1.04) and 0.93 (0.83-1.04)]. Compared to the first quintile of calcium intake, second, third, fourth, but not fifth quintiles were associated with fewer incident strokes: respective HR 0.84 (0.72–0.97), 0.83 (0.71–0.97), 0.78 (0.66–0.92) and 0.95 (0.78–1.15). The meta-analysis results suggest that high levels of calcium intake were associated with decreased all-cause mortality, but not cardiovascular mortality, regardless of average calcium intake. Calcium supplementation was associated with cardiovascular and all-cause mortality amongst women, but not men. Moderate dietary calcium intake may protect against cardiovascular and all-cause mortality and incident stroke. Calcium supplementation may reduce mortality in women.

3 February 2020 in Global Heart
Verified
Journal Article
Open access
PDF file
WSWeronika A. Szlachetka
Weronika A. Szlachetka
TPTiberiu Pana
Tiberiu Pana
STSomsak Tiamkao
Somsak Tiamkao
ACAllan B. Clark
Allan B. Clark
KKKANNIKAR KONGBUNKIAT
KANNIKAR KONGBUNKIAT
Phyo MyintPhyo Myint
Phyo Myint
Patients with diabetes mellitus (DM) have been found to be at an increased risk of suffering a stroke. However, research on the impact of DM on stroke outcomes is limited. We aimed to examine the influence of DM on outcomes in ischaemic (IS) and haemorrhagic stroke (HS) patients. We included 608,890 consecutive stroke patients from the Thailand national insurance registry. In-hospital mortality, sepsis, pneumonia, acute kidney injury (AKI), urinary tract infection (UTI) and cardiovascular events were evaluated using logistic regressions. Long-term analysis was performed on first-stroke patients with a determined pathology (n = 398,663) using Royston-Parmar models. Median follow-ups were 4.21 and 4.78 years for IS and HS, respectively. All analyses were stratified by stroke sub-type. Mean age (SD) was 64.3 (13.7) years, 44.9% were female with 61% IS, 28% HS and 11% undetermined strokes. DM was associated with in-hospital death, pneumonia, sepsis, AKI and cardiovascular events (odds ratios ranging from 1.13–1.78, p < 0.01) in both stroke types. In IS, DM was associated with long-term mortality and recurrence throughout the follow-up: HRmax (99% CI) at t = 4108 days: 1.54 (1.27, 1.86) and HR (99% CI) = 1.27(1.23,1.32), respectively. In HS, HRmax (t = 4108 days) for long-term mortality was 2.10 (1.87, 2.37), significant after day 14 post-discharge. HRmax (t = 455) for long-term recurrence of HS was 1.29 (1.09, 1.53), significant after day 116 post-discharge. Regardless of stroke type, DM was associated with in-hospital death and complications, long-term mortality and stroke recurrence.